Abstract: Chronic lymphocytic leukemia (CLL) in a patient is treated by administering to the patient oxidatively stressed CLL cells. The CLL cells are oxidatively stressed extracorporeally, e.g. by subjection to oxygen/ozone mixtures, and preferably are simultaneously subjected to other stressors such as UV light. Preferably also, the CLL cells are autologous, and are contained in an aliquot of the patient's blood at the time of subjection to stressing.

Abstract: As disclosed herein, the present invention is directed to a novel system for monitoring cell movement in response to chemotactic and chemokinetic factors. In this system, cells migrate in an under-agarose environment and their position is monitored using a system capable of measuring changes in impedance and other electrical parameters of the system at a target electrode lithographed onto a substrate as the cells arrive at the target. With the disclosed system, the time of arrival of cells at the target electrode is proportional to the dose of the chemoattractant species used to stimulate the cells and can be assessed by changes in resistance at the electrode. The system is readily able to distinguish between wild-type cells and mutants that are deficient in their chemotactic response. In addition, agents that interfere with chemotactic motility can be shown to lead to delayed arrival of cells at the target electrode.

Abstract: Methods to inhibit hot flashes or gynaecomastia in a subject are provided. In the methods of the invention, an LHRH antagonist is administered to a subject in need of treatment for hot flashes or gynaecomastia such that hot flashes or gynaecomastia are inhibited in the subject. In a particularly preferred embodiment, the invention provides a method for inhibiting menopause-related hot flashes in which an LHRH antagonist is administered to a subject in need of treatment for menopause-related hot flashes such that the hot flashes are inhibited in the subject.

Abstract: Provided herein is a novel and useful Ligand comprising a peptide comprising an amino acid sequence of SEQ. ID. NO.:6, an analog, a derivative, or a variant thereof, which increases the absorption of biological agents across the blood brain barrier and the gastrointestinal barrier. As a result, a Ligand of the present invention increases the bioavailability of biological agents administered orally.

Abstract: The invention relates to a pharmaceutical preparation which consists of or contains cyclosporin A, an emulsifying &agr;-tocopherol derivative, an ethoxylation product of vegetable oils, fatty acids or fats as a further emulsifier and a pharmaceutically customary alcohol.

Abstract: A method is provided for removing citrate, aluminum, and other multivalent ions and contaminants from proteins by adjusting the pH of a solution containing the protein to a pH from about 7 to about 10, and diafiltering the pH-adjusted solution against aqueous solutions which have a low level of ions.

Abstract: This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase. The inhibitors are short, synthetic peptides in which the P2 moiety is substituted with various nitrogen-containing heterocyclic groups. As inhibitors of human neutrophil elastase, the compounds are useful in the treatment of a patient afflicted with a neutrophil associated inflammatory disease.

Abstract: The activation of cyclin dependent kinase 5 (Cdk5) depends on the binding of its neuronal specific activator Nck5a. The minimal activation domain of Nck5a has been experimentally determine comprise acid residues 150 to 291 of the protein. It has been demonstrated that a 28 residue peptide encompassing amino acid residues Ala 146 to Asp 173 of Nck5a is capable of binding Cdk5 and hence resulting in the inhibition of its Kinase activity. Additionally, this peptide could also inhibit Cdk2 with a similar potency as it does to Cdk5. The direct competition experiments showed that the Nck5a inhibitory peptide does not compete with Nck5a for Cdk5 or cyclin A for Cdk2. Steady state kinetic analysis indicated that the Nck5a peptide acts as a non-competitive inhibitor of Cdk5/Nck5a complex with respect to its substrate.

Abstract: The invention relates to the use of peptide amides of formula (I) and phenylamino-oxoacetic acid derivatives of formula (II) as well as the salts of the above compounds as active substances for the preparation of pharmaceutical compositions possessing neurogenic and non-neurogenic antiinflammatory as well as analgetic effects.

Abstract: A composition in unit dosage form for the inhibition, prevention or treatment of inflammatory bowel disease comprising an effective amount of a compound having the formula: and a pharmaceutically acceptable carrier therefor.

Abstract: This invention pertains to the discovery of a class of reagents that effectively form intramolecular disulfide bonds in peptides. Intermolecular disulfide linkage formation is low or essentially non-existent. In addition, preferred reagents of this invention are relatively mild and do not oxidize “vulnerable” residues in the subject peptide(s). In addition the reagents and reaction products are safe and essentially non-toxic. One particularly preferred reagent is [Pt(en)2Cl2]2+ where en is ethylenediamine.

Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

Abstract: Compositions and methods for use with substrates which are useful in the sustained delivery of bioeffecting agents are described. The compositions of the invention include a multicomponent complex which attaches a bioeffecting agent to a substrate with an anchor provided by a linker compound which also forms a cleavable linkage so that the bioeffecting agent's release into the area surrounding the substrate occurs in a sustained manner over an extended period of time. The methods of the invention involve providing a bioeffecting composition on the surface of a substrate so that a bioeffecting agent may be released in a sustained manner over time.

Abstract: The present invention relates to compounds of formula I: where R5 is a sugar moiety. The compounds are useful in inhibiting fungal and parasitic activity and infections.

Abstract: Disclosed is a nitric monoxide metabolite-polyoxyalkylene-hemoglobin complex having a molecular weight of from 100,000 to 2,000,000 daltons, in which a polyoxyalkylene derivative is bound to from 10 to 30% in total of bindable amino groups in hemoglobin and a nitric monoxide metabolite is bound to from 10 to 100% in total of thiol groups of cysteine residues.

Abstract: A drug delivery system and methods are provided wherein a therapeutic/diagnostic agent or a component of the immune system is directed to particular cells in a selected organ or a specific site. Such a system can be formed by a photoselective compound generally described as V-M-P-C. V is a vector component suitable to target particular cells in a selected organ or site, where the type of the cell or antigen does not have to be specific to the desired treatment site. M is a marker component that is capable of being targeted by a therapeutic/diagnostic agent or a component of the immune system. P is a photocleavable or photosensitive bond, and C is a cap component rendering M ineffective. C is connected to M by the photocleavable or photosensitive bond. The photoselective compound is administered and marks targets of a certain kind of cell or a specific site.

Abstract: Methods for modulating amyloid deposition in a subject are described. An effective amount of at least one ATP binding cassette (ABC) transporter blocker is administered to a subject, such that modulation of amyloid deposition occurs. Methods also include administering and effective amount of at least one ABC transporter blocker, or a pharmaceutically acceptable salt thereof, to a subject such that a disease state associated with amyloidosis is treated. Packaged pharmaceutical compositions for treating amyloidosis are described. The package includes a container for holding an effective amount of a pharmaceutical composition and instructions for using the pharmaceutical composition for treatment of amyloidosis. The pharmaceutical composition includes at least one ABC blocker for modulating amyloid deposition in a subject. Methods for identifying agents which modulate amyloid deposition in a subject are also described.

Abstract: There is provided soybean protein products of significantly lowerstachyose content as a function of an improved soybean having a seed stachyose content of less than 50 &mgr;mol/g. Improved soybean lines are provided as are methods of using such reduced stachyose soybeans.

Abstract: L-Lys-L-Glu dipeptide is proposed for use in medicine for preparation of a drug capable of stimulating repair processes. According to the invention, the pharmaceutical peptide preparation capable of stimulating regeneration consists of pharmaceutically admissible carrier and effective quantity of dipeptide as an active part, which is a combination of, L-lysil-L-glutamic acid or its salts. The pharmaceutical peptide preparation is proposed for parenteral, intranasal oral and local application. According to the invention, the method stimulating regeneration consists of prophylactic and/or treatment injections of the drug in the dose of 0.01-100 &mgr;kg per per 1 kg of weight, at least once a day during a period necessary for obtaining a therapeutic effect.

Abstract: A method for manufacturing polycarbonate by melt-polycondensing bisphenol and carbonic acid diester uses as catalyst an alkali metal compound and/or alkaline earth metal compound (a). The catalyst is added to the bisphenol prior to the melt polycondensation, in an effective amount, i.e., the amount of alkali metal compound and/or alkaline earth metal compound (a) that acts effectively as a catalyst, is contained in said bisphenol, and is controlled to have the same catalytic activity as 1×10−8 to 1×10−6 mole of bisphenol disodium salt per mole of pure bisphenol A. The method conducts the reaction efficiently from the initial stage in a stable manner to obtain polycarbonate with good color, good heat stability and color stability during molding and the like.